FDA Approves Livtencity (maribavir) for Post-Transplant Cytomegalovirus (CMV) Infection/Disease

- In the Phase 3 SOLSTICE study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R) CMV infection/disease achieved confirmed CMV DNA level<LLOQ at Week 8 with Livtencity (56%; n=131/235), compared to...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news